SCHEMBL7811207

SCHEMBL7811207

Cc1ccc(NC(=O)Nc2ccccc2)cc1NS(=O)(=O)c1cccc(-c2ccc(F)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
MAPT P10636 3/20 0.55
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
MAPK1 P28482 2/20 0.55
STING1 Q86WV6 1/20 0.53
CNR1 P21554 1/20 0.53
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
IDH1 O75874 5/20 0.52
IDH2 P48735 6/20 0.52
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
CASP3 P42574 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11956180 0.94 DDX3X (0.51) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7798880 0.92 MAPT (0.55) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7805405 0.89 ITGB3 (0.51) LMNAMAPTKMT2ASTING1KDM4E
SCHEMBL7805723 0.88 CNR1 (0.58) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7805415 0.88 GHSR (0.54) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7804642 0.87 KMT2A (0.70) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7805558 0.87 IDH2 (0.61) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7805307 0.87 DDX3X (0.50) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7804129 0.86 PFKFB3 (0.60) LMNAMAPTKMT2AMEN1MAPK1
SCHEMBL7806992 0.86 CNR1 (0.58) LMNAMAPTKMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B LMNA 2594/4885MAPT 2831/4885KMT2A 2144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.